#Ireland #Dublin #Theravance Biopharma #YUPELRI #BTIG Conference

Theravance Biopharma's Upcoming Conference Participation

Theravance Biopharma, Inc. (NASDAQ: TBPH), a company dedicated to enhancing patients' lives through its innovative medicines, is gearing up for an important event in the biotechnology sector. On July 30, 2025, the company will be engaging in a fireside chat at the BTIG Virtual Biotechnology Conference scheduled for 12:00 PM ET (9:00 AM PT/5:00 PM IST). This annual conference serves as a platform for biotechnology firms and investors to connect, share insights, and discuss advancements in the industry.

As part of the event, senior management from Theravance Biopharma will be on hand to host one-on-one meetings, allowing investors and interested parties to gain deeper insights into the company's strategic direction and innovative pipeline. For those interested in attending the webcast or setting up discussions with Theravance's management, inquiries can be directed to BTIG representatives or via email to their investor relations team.

About Theravance Biopharma

Founded with a mission to deliver Medicines that Make a Difference®, Theravance Biopharma leverages years of expertise to develop groundbreaking treatments. The company has made significant strides in the biotechnology field, particularly with its FDA-approved inhalation solution, YUPELRI® (revefenacin), used for the long-term management of patients suffering from chronic obstructive pulmonary disease (COPD). With a focus on patient-centric approaches, Theravance is committed to advancing healthcare solutions that address unmet medical needs.

Currently, Theravance is also exploring late-stage developments with Ampreloxetine, a once-daily norepinephrine reuptake inhibitor that is designed to treat symptoms associated with neurogenic orthostatic hypotension (nOH) in patients diagnosed with Multiple System Atrophy (MSA). This investigational therapy holds the promise of becoming a first-in-class treatment targeting a complex set of symptoms, enhancing the quality of life for patients affected by this challenging condition.

Investor Opportunities

The BTIG Virtual Biotechnology Conference represents a crucial opportunity for Theravance Biopharma to connect with investors and stakeholders in the biotechnology landscape. By engaging directly with senior management, attendees can expect to gain valuable insights into the company’s operations, research and development initiatives, and growth strategies aimed at driving shareholder value.

For more details about Theravance Biopharma and its innovative products, visit their official website at www.theravance.com. The company’s commitment to improving patients' lives through strategic development and high-impact therapies reflects its mission in today’s rapidly evolving healthcare environment.

Conclusion

As the date for the BTIG Virtual Biotechnology Conference approaches, anticipation builds among investors and healthcare professionals alike. Theravance Biopharma's participation underscores its ongoing dedication to pioneering medical advancements that address critical health challenges. The company's innovative drug portfolio and strategic focus on patient care position it as a significant player in the biopharma industry.

Stay tuned for updates and insights during and after the conference, reflecting the ongoing progress and commitments made by Theravance Biopharma in its quest to improve patient health worldwide.